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Advances in the Radiation Therapy 
of Carcinoma of the Prostate 
Joel Elliot White, MD* 
6as/c principles of radiation biology and 
radiadon tolerance are reviewed. The Im-
plications for radiation therapy of newer 
staglngtechniques In carcinoma of the pros-
tate such as exploratory laparotomy, 
lymphangiography, and bone marrow acid 
prosphatase are discussed. A technique for 
treating the prostate and para-aortic lymph 
nodes in continuity is presented. Complica-
tions and results of therapy are discussed. 
S A u c h change has taken place in the roleof 
radiation therapy in the treatment of car-
cinoma of the prostate. Improvement in 
radiation therapy equipment and the de-
velopment of sophisticated treatment plan-
n i n g t e c h n i q u e s are o n l y p a r t i a l l y 
responsible. The greater stimulus has come 
from the advances in staging procedures, 
such as lymphography, staging laparotomy, 
and bone marrow acid prosphatase, which 
have already been discussed by others. 
In only 5% of patients is cancer clinically 
confined to the prostate. About VA to Vi of 
these wil l have evidence of extraprostatic 
extension when radical prostatectomy is 
peri^ormed. We also know that the incidence 
of lymphatic metastases is very high in this 
group of patients. We suspect, but have not 
yet proven, that many of these patients are 
potentially curable. However, much larger 
volumes of tissue than previously treated 
must be irradiated. 
* Head, Clinical Division, Department of Thera-
peutic Radiology 
Also PRESENTED AT THE DETROIT UROLOGI-
CAL SOCIETY, JANUARY, 1975 
Address reprint requests to Dr. White at Henry 
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Radiation Biology 
In order to comprehend the sign if icance of 
these changes in radiation therapy one must 
first understand some of the basic principles 
of radiation interactions with biological sys-
tems. As radiation passes through tissues, it 
causes alterations at the biochemical level 
primarily through the mechanism of ioniza-
tion. At the cellular level, the effects appear 
principally to be mediated by chromosomal 
damage. The effects we see clinically are the 
resultof disruption of tissues and organs due 
to cellular damage interacting with home-
ostatic mechanisms of the body. 
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Figure 1 
Isoeffect curves relating the total dose to the 
overall treatment time for A, skin necrosis; B, 
cure of skin carcinoma; C, moist desquamation of 
skin; D, dry desquamation of skin; E, skin 
erythema. (From Eric J. Hail, Radiobiology for the 
Radiologist, Hagerstown, Maryland 1973, Harper 
& Row Co. Redrawn from Strandqvist M: Acta 
Radiol Supp 55:1-300,1944) 
The abi l i ty of the body's homeostatic 
mechanisms to repair the damage due to 
radiation is dependent upon four main con-
siderations: the time interval during which 
radiation is administered, the total dose of 
radiation, the fractionation or size of each 
dose, and the volume of tissue irradiated. 
The first correlations of dose and time 
were published by Strandqvist in 1944. In 
Figurel curve A shows skin necrosis, curve B 
tumor control, and curves C, D, and E 
various degrees of skin reaction. Note that, 
according to these data, the dose which wi l l 
cause skin necrosis is above that for tumor 
control at all levels. 
The curves in Figure 2 summarize data 
which not only take into account the effects 
of total dose and time, but also include the 
effects of volume. The solid lines represent 
99% tumor control. The dotted lines repre-
sent a 3% incidence of skin necrosis. There 
are two sets of curves accordingtothe size of 
the field, three square centimeters and thirty 
square centimeters. These observations have 
been made on skin carcinoma. They repre-
sent an optimal range of doses which are 
adequate to control the tumor in a majority 
of cases, w i t h an acceptable level of 
complications. 
Figure 2 
Time-dose-volume relationships for fractionated 
irradiation of carcinoma of the skin. The solid 
lines are isoeffect curves for 99% tumor regres-
sion for cancers 3 cm^ and 30 cm^. The broken 
lines are isoeffect curves for 3% skin necrosis for 
skin areas of 3 cm^ and 30 cm^ The curves for 
tumor regression have less slope than those for 
skin tolerance. Unlike the classical Strandqvist 
curves, cancers of similar sizes are grouped 
together, emphasizing that larger cancers require 
a higher dose than small cancers. The curves also 
emphasize that for a given fractionation large 
volumes tolerate less dose than small volumes. 
Moving along the graph from left to right, with 
increased fractionation the curves for necrosis 
and tumor regression cross, then diverge, empha-
sizing the benefits of fractionation. (From Moss 
WT, Brand WN, and Battifora H: Radiation On-
cology, ed 4, St. Louis, 1973, The C. V. Mosby 
Co., modified from von Essen CF: Radiology 
81:881-883,1963) 
For the three square centimeter field the 
single dose for both skin necrosis and tumor 
control are reasonably close together. As the 
dose and the t ime increase, the curves 
rapidly diverge, indicating an increasing dif-
ferential margin of safety. For example, at 20 
days about 4000 rads is required for tumor 
control while the skin wi l l tolerate about 
7000 rads. A dose adequate to control the 
tumor can be delivered without a significant 
risk of complications. 
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Forthe thi r ty square cent imeter f ie ld , 
however, the single dose required for tumor 
control is much greater than that which wi l l 
produce skin necrosis. As one follows the 
curves out in time, one can see that even-
tually they cross, (in this case 5000 rads at 28 
days) and reach a point where the dose 
required for tumor control is less than that 
required for skin necrosis. This illustrates 
graphically the principles of protraction and 
fractionation. That is, as one reduces the 
daily dose but increases the overall time and 
total dose delivered one can gain a therapeu-
tic advantage by increasing the differential 
between tumor control and normal tissue 
tolerance. They also emphasize the impor-
tance of volume: The larger the volume the 
less the normal tissue tolerance and the 
greater the dose required for tumor control. 
While the skin is relatively resistant to 
radiation, a majority of internal organs are 
not. However, the solid tumors which com-
prise a majority of internal malignancies 
require about the same high doses for con-
trol as do malignancies of the skin. Tolerance 
is dependent on how much of the organ is 
irradiated. The fol lowing illustrations wil l be 
important to keep in mind when discussing 
our newer techniques. Radiation myelitis 
produces a Brown-Sequard syndrome if Va 
the diameter of the cord is involved, or a 
transection if the entire width is involved. 
Spinal cord tolerance is shown to be depen-
dent onthe length of spinal cord irradiated. If 
the length of cord treated is relatively short, 
radiation myelitis wi l l usually occur only 
after doses in the range of 4400 to 5000 rads 
in 4V2 to 5 weeks. If a greater length of spinal 
cord is irradiated, the risk is increased and 
the tolerance decreased to a range of 3 600 to 
4000 rads in about 4 weeks. 
The syndrome of acute nephritis is pro-
duced in about V2 of patients if the dose to 
the whole of both kidneys exceed 2300 rads 
in about 5 weeks. However, if V2 to Vs of 
each kidney is shielded in such a manner as 
to restrict the dose to less than 2000 rads, the 
remaining portions of the kidney may be 
treated to higher doses without clinically 
significant alterations in function. Similarly, 
the radiation tolerance of most organs, such 
as liver, small bowel and lung, is considera-
bly diminished if the entire organ must be 
included in the radiation field. If only a 
portion of the organ is irradiated, however, 
relatively high doses wi l l be tolerated. 
What about tumor control? We have seen 
from the earl ier curve (Figure 2) that as tumor 
size increases, the dose for tumor control 
also increases. There are several reasons for 
this. One is that cell kill or survival follows 
an exponential curve if the cells are well 
oxygenated. As the tumor grows larger, 
however, the central portion of the tumor 
becomes hypoxic and therefore radioresist-
ant. Calculations based on experimental val-
ues obtained by Warburg and Crowe have 
indicated that oxygen concentration wil l fall 
to zero about 150 microns from capillaries. 
Cells more distant than this wi l l be anoxic. 
Experimentally in animals it has been shown 
that cel ls closer to vascular stroma are 
damaged more than those distant from it 
during radiation even though those further 
from the vasculature may receive higher 
doses. Tomlinson and Grey examined the 
histological structure of human lung tumors. 
They noted that the solid tumor cords were 
surrounded by vascular stroma but no capill-
aries were seen in the cords. Al 1 cords greater 
than 180 microns in radius had necrotic 
centers. There is, as wel l , a transitional zone 
of hypoxia in which the cells are still viable 
but metabolically inactive due to a lack of 
oxygen and nutrients. With a course of 
f ract ionated rad ia t ion, most radiat ion 
therapists feel that the more peripheral, well 
oxygenated cells are initially killed. As the 
tumor regresses, they bel ieve that re-
oxygenation occurs because the surviving 
previously hypoxic cells become closer to 
the vascular supply and are rendered euoxic 
and thus more sensitive to radiation. Re-
oxygenation, however, is not accomplished 
100% of the time. 
How does this affect tumor dose? For 
grossly evident tumors and employ ing 
megavoltage radiation such as cobalt 60 or 
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linear accelerators, permanent local control 
of most solid tumors requires doses in the 
range of 6600 to 7000 rads, whether they a re 
epidermoid carcinomas of the head and 
neck region or adenocarc inoma of the 
prostate. 
/Vlicroscopic disease, on the other hand, 
does not require such high doses. Fletcher 
and others have demonstrated that doses in 
the range of 5000 rads in five weeks, deliv-
ered to clinically uninvolved but high risk 
nodes, wi l l prevent tumor development in 
90% of cases. In our own series at Henry 
Ford Hospital, many patients with Stage 1 
and llA carcinoma of the cervix received 
pre-operative radiation. The dose to the 
pelvic lymph nodes is inthe range of 3200 to 
3600 rads. Several previous studies have 
demonstrated thatthe expected incidence of 
nodal involvement would be about 10 to 
20% in this patient group. However, only 
one patient in our series had positive nodes 
in the surgical specimen. The conclusion 
that one is led to draw from this evidence is 
that microscopic clumps of cells are proba-
bly much more radiosensitive than mac-
roscopic aggregates. 
The implication in carcinoma of the pros-
tate is that while some of these tumors are 
beyond the confines of surgical extirpation, 
they may still be permanently controlled by 
radiation, if the following criteria can be 
met: 
1. A radiation portal sufficient in size to 
encompass all the known and suspected 
areas of disease can be employed. 
2. No vital organs wil l be included in the 
high-dose volume. 
3. A sufficient amount of radiation can be 
acl ministered to sterilize the tumor with-
out exceeding normal tissue tolerance. 
The use of such things as exploratory 
laparotomy for surgical staging and 
lymphangiography have shown that car-
cinoma of the prostate frequently metasta-
sizes to regional nodes and may remain 
there priorto hematogenous dissemination. 
The implication is that radiotherapists in 
recent years are treating larger volumes of 
tissue to higher doses. Tolerance of normal 
tissue must be respected, for it is of no value 
to sterilize the tumor and in the process 
cause unacceptable complications. 
Treatment Technique 
Since solid tumors, as previously stated, 
require high doses of radiation forcontrol, in 
the range of 6000 to 7000 rads, reduction of 
the treatment volume to minimal size is 
essential. The same staging procedures 
which define the extent of disease allow 
visualization and minimization of the neces-
sary treatment volume. These factors have 
stimulated trials of the aggressive radiation 
therapy. 
The specific technique we use depends on 
the extent of tumor as shown by the staging 
procedures. In patients whose disease is 
confined to the prostate or extraprostatic 
tissues, we know that the risk of pelvic lymph 
node involvement is relatively high. If the 
lymph nodes are shown to be negative by 
lymphangiography a n d / o r exploratory 
laparotomy, we initially treat the entire pel-
vis to a dose of 5600 rads. This dose should 
be adequate to control microscopic disease 
that may be clinically undetected in the 
lymph nodes. A booster dose of an addi-
tional 1000 rads is then delivered to the area 
of the primary tumor site to bring the total 
dose to this area to 6600 rads delivered in 
6V2 weeks, giving 200 rads per day, five days 
per week. 
Once the lymphatics are grossly involved, 
we feel that it is necessary to treat the entire 
abdominal lymphaticchain uptothe level of 
thediaphragm.Atechniquetotreatthis large 
area has been developed here at Henry Ford 
Hospital. Initially, an anterior posterior co-
axial pair of fields, referred to as a spade, 
(Figure 3) is used to encompass the primary 
tumor as well as lymphatics up to the dia-
phragm. This field is treated at the rate of 150 
rads per day in order to reduce the daily dose 
rate to the lower spinal cord segment as well 
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Figure 3 
The spade shaped field. This is designed to en-
compass the lymphatics of the pelvis and the 
para-aortic chain up to the level of the 
diaphragm. 
as the small bowel. The kidneys are not in 
this field. Lateral pelvic fields are also treated 
during this time so as to boost the daily dose 
to the prostate and pelvis to 200 rads. 
In order to avoid the complication of 
radiation myelitis and small bowel necrosis 
caused by delivering the entire course of 
radiation through the co-axial pair, rota-
tional therapy with a 60° posteriordropout is 
given on alternate weeks. The para-aortic 
port (Figure 4) is again treated at 150 rads per 
day. The pelvic port is treated at 200 rads per 
day. Computer generated isodose curves are 
obtained and then superimposed on a con-
tour of the patient's body (Figure 5) which 
contains the kidneys (as outlined by ultra-
sonography) and the spine (as demon-
strated on transverse tomography) . The 
rotation is designed so as to deliver a max-
Figure 4 
Separate pelvic and para-aortic ports. The pelvic 
port extends to the L4,5 intervertebral disc space. 
The para-aortic ports encompass the remainder 
of the para-aortic lymph nodes up to the level of 
the diaphragm. The pelvic port is treated at the 
rate of 200 rads per day and the para-aortic port 
at the rate of 150 rads per day. 
imum dose to the central volume of interest 
while giving smaller amounts of radiation to 
the surrounding tissues. The kidneys, which 
were not in the radiation beam at all for the 
co-axial fields, are demonstrated to lie in the 
50-60% dose region of the rotation. Most of 
the bowel outside of the central volume wi l l 
receive much lower doses. The spinal cord is 
seen to lie within the 40-50% dose region. 
The overall treatment scheme is sum-
marized in Table 1. Note thatthe para-aortic 
nodes are treated at the rate of 750 rads per 
week while the pelvis is treated at 1000 rads 
weekly. In the sixth week, the pelvis has 
reached 5600 rads, the maximum dose this 
volume wi l l tolerate. The spade field is 
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TABLE TABLE II 
WEEKLY DOSE (RADS) 
WMk "Spade" 
Pelvic 
Boost 
Para-
Aortic Pelvis 
Prostate 
Boost 
1 7S0 25C 
750 1000 
~ 
3 750 250 ~ - -
4 - 1000 ~ 
5 750 25C - - -
6 ~ 750 600 400 
Co-Axial 
Opposed 
Para-Aortic 
7 MX) 
8 -
150 
300 
— 600 
Summary of the overall treatment technique. On 
odd weeks, the spade shaped field is treated with 
a small lateral field to boost the pelvis. During the 
middle of the sixth week, the larger pelvic field 
has reached a total dose of 5600 rads and the 
smaller booster field to the area of the prostate 
has been started. During the first four treatments 
of the seventh week, the para-aortic port is 
treated to a coaxial opposed field. During this 
week also, the booster field to the prostate is 
completed. 
Theratron 
CO Rototion 
60*posterior dropout 
Figure 5 
Computer generated isodose curves superim-
posed on a contour of the body. Note that the 
lymph nodes and spine are located as visualized 
on transverse tomography and the kidneys are 
located as demonstrated by ultrasonography. 
TOTAL DOSES (PARA-AORTIC) 
"Spade" 2250 rads 
Co-Axial 
Para-Aortic 600 rads 
Rotational 
Para-Aortic 2700 rads 
Total Para-Aortic 5550 rads (7 1/2 weeks) 
Total doses to the para-aortic nodes by the com-
bination of techniques. 
decreased to a co-axial pair over the para-
aortic nodes while the dose to the prostate is 
boosted with a small field. The para-aortic 
nodes receive a total dose of 5550 rads in 7'72 
weeks (Table II). This dose should be ade-
quate to control microscopic disease. The 
pelvis receives 5600 rads in 51^ 2 weeks (Ta-
ble III), the prostate receives an additional 
1000 rads with a small field designed to 
encompass only the prostate and its bed. 
This increases the total dose to the prostatic 
region to 6600 rads in 614 weeks. 
Using this alternate week technique, 
doses to critical organs are 1 im ited (Table IV). 
The kidneys receive a total dose in the range 
of 1200-1400 rads in 6y2 weeks. The spinal 
cord and the entire small bowel receive 
doses of about 3810 rads in 7y2 weeks. 
Finally, localized areas of small bowel wi l l 
receive 5500 rads over 71^ 2 weeks. 
Results Of Therapy 
There have been reports in the literature of 
biopsy-proven residual tumor after radiation 
therapy. The incidence of post radiation 
residual tumor varies considerably (Table V) 
from a low of 24% up to a high of 87%. In 
none of these series was there an attempt to 
obtain biopsy from every patient who was 
treated. Most of the biopsies were from 
patients in whom, for some reason, there 
was a suspicion of residual tumor. Many of 
the patients, especially those with a higher 
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TABLE III 
TOTAL DOSES (PELVIS) 
"Spade" 2250 rads 
Pelvic Boost 750 rads 
Pelvic Rotation 2600 rads 
Total Pelvis 5600 rads (5 1/2 weeks) 
Prostate Boost 1000 rads 
Total Prostate 6600 rads (6 1/2 weeks) 
A summary of the total doses delivered to the 
pelvis and prostate by the various techniques. 
TABLE IV 
TOTAL MAXIMUM DOSES (CRITICALORGANS) 
Kidney 1200 rads (6 1/2 weeks) 
Spinal Cord 3810 rads (7 1/2 weeks) 
Localized S. B. 5500 rads (7 1/2 weeks) 
Whole Bowel 3810 rads (7 1/2 weeks) 
TABLE V 
Total maximum doses to critical organs. 
percentage of positive biopsies, initially had 
more extensive tumors. 
Cox and Tijerina reported positive for 
tumor 26 of 43 biopsies obtained the first 
nine months post radiation. Twenty of these 
became negative over the next one to two 
years. They emphasize that tumors which 
are slow growing also regress slowly after 
irradiation. 
The question that must be asked is not 
whether there is actually residual tumor, but 
"what Is the clinical significance of this 
residual tumor?" The old-time radiothera-
pists used to say that radiation therapy never 
POST RADIATION RES 1 DUAL TUMOR 
RHAMY etaL (J. UROL, 1972) 877. (13/15) 
BAGSHAW eLaL (RADIOL 19651 (M' ( 3/5 ) 
GROUT eLal (J. UROL., 1971) 45»i ( 5/11) 
HILL et al (CANCER, 1974) 24% ( 5/21) 
Percent of post radiation residual tumor within 
the prostate as reported by various authors. 
TABLE VI 
RESULTS OF TREATMENT -10 YEARS 
(disease limited to prostate)' 
RADICAL PROSTATECTOMY (JEWITT, 1954, 1969) 49% 
ORCHIECTOMY AND ESTROGENS (BARMES, 1969) M 
RADICAL IRRADIATION (BAGSHAW, 19731 48% 
Results of treatments for carcinoma of the pros-
tate utilizing various techniques as reported by 
various authors. 
cured a cancer, but rather prevented further 
growth. It has long been known in such 
things as cancer of the cervix, for instance, 
that patients who are treated with radiation 
therapy and who undergo pelvic surgery for 
some other cause, as long as 20 to 25 years 
later, may suddenly have reactivation of 
their tumor. In most cases this suggests that 
radiation induces a fibrotic reaction which 
entraps the tumor cells. Perez et al demon-
strated prostatic fibrosis following irradia-
tion. Most articles reporting post radiation 
residual have not mentioned the presence or 
absence o f th i s phenomenon. However, 
from our point of view, the presence or 
absence of apparent residual tumor on bi-
opsy is not as important a factor as the results 
of therapy. 
jewitt reported the largest series of patients 
treated with radical prostatectomy (Table 
VI). Even with improvements of the tech-
nique over the years between 1955 and 
1970, there has been no marked improve-
189 
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Actuarial survival 
I I I 
3 4 5 6 7 8 9 1 0 
Survival in ^ecir*s 
limited foprost 
mean age 62 
160 pts. 
Extracap. ext 
mean age: 64, ISO pts. 
J I L 
Figure 6 
Results of radiation therapy treatments from 
Gordon R. Ray et a l , " D e f i n i t i v e Radia t ion 
Therapy For Carcinoma Of The Prostate", Radi-
o logy , 106, February, 1973, pages 407-418, 
Figure 2. 
Figure 7 
Bone scan six months after treatment of a patient 
showing densely positive areas of uptake repre-
senting metastatic disease. Note that the areas of 
metastasis start right at the upper border of the 
radiation therapy treatment portal. 
ment in the results. That is, in patients receiv-
ing radical prostatectomy for disease l im i ted 
to the prostate, the overa l l 10 year survival or 
10 year " c u r e ra te " is abou t 5 0 % . In 1969 
Barnes reported a series in w h i c h o n l y or-
ch iec tomy and estrogen therapy we re ad-
min is tered to patients w i t h disease l im i ted to 
the prostate. This series w o u l d be somewha t 
p re jud iced by the fact that many of these 
patients w i l 1 not have disease con f ined to the 
p r o s t a t e g l a n d i tse l f . F i n a l l y , in 1 9 7 3 , 
Bagshaw reported the i r results o f therapy 
using a techn ique analogous to ours, that is, 
i r rad iat ing the lymphat ics as w e l l as the 
prostate g land . They have an overa l l 10-year 
survival again of a round 5 0 % . It is of ma jo r 
interest, however , t h a t m a n y of their patients 
had more advanced disease and w o u l d not 
be candidates for radical prostatectomy. 
F igu re 6 r ep resen t s a c t u a r i a l s u r v i v a l 
curves taken f rom Bagshaw's data. A t t h e top 
is a p ro jec t ion of survival for a popu la t ion of 
normal m e n w i t h a mean age of 63 . The 
survival in the g roup of treated patients 
obv ious ly is not as good as in normal i nd i -
v idua ls . However , in those w i t h disease 
l im i ted to the prostate g land , survival was 
fa i r ly c lose to normal expectancy . The result 
was 4 8 % at 10 years. A n impor tant fact he 
noted was that, in 8 5 % of the patients w i t h 
disease l im i ted to the prostate, more than 
half of the prostate g land was invo lved by 
t umor ; so this was not a g roup o f patients 
w i t h ear ly disease. The survival rate was 
3 0 % for patients in w h o m there was extra-
capsular ex tens ion. This is reasonably good 
w h e n c o m p a r e d w i t h o t h e r m e t h o d s o f 
therapy for this stage. 
C o m p l i c a t i o n s 
As radiotherapists, w e l ike to d is t inguish 
between w h a t w e consider comp l i ca t i ons 
and sequela of rad ia t ion therapy. There are 
cer ta in expected react ions to the rad iat ion 
w h i c h general ly w i l l remi t w i t h i n several 
weeks after c o m p l e t i n g therapy. In ou r ser-
ies, al l patients were able to comp le te their 
course of therapy. Bagshaw's exper ience 
w i t h this large number of patient's was that 
approx imate ly 4 0 % of patients exper ience 
acute gastrointest inal or gen i tour inary symp-
toms. He also stated that there we re approx-
imate ly 1 1 % of patients w h o had symptoms 
w h i c h persisted for u p t o one year. However , 
it was very rare that patients had symptoms 
190 
Radiation in Prostate Carcinoma 
lasting longer than that. Bagshaw felt that 
persistent morbid ity existed when complica-
tions were related either to initial tumor 
extent or prior surgical procedures. Exam-
ples were patients in whom there was per-
sistent tenesmus. In this group of patients it 
was noted that the anal sphincter was in-
vaded by tumor prior to the initiation of 
therapy. It is a known phenomenon that 
f ibrosis occurs as the tumor regresses. 
Urethral strictures were confined almost en-
tirely to patients who had undergone trans-
urethral resection prior to in i t ia t ion of 
therapy. In the latter years of their study they 
found that the incidence of urethral stricture 
decreased markedly if they waited fourto six 
weeks after transurethral resection before 
undertaking radiation therapy. Impotence 
occurs in essentially 100% of patients who 
undergo radical prostatectomy or orchiec-
tomy with estrogen therapy. In Bagshaw's 
series, a total of 96 patients reported normal 
sexual function following therapy. 
Figure 7 from our files illustrates the new 
questions we have created. This bone scan is 
of a 70-year-old gentleman with prostatic 
obstruction who was found to have ade-
nocarcinoma at the time of transurethral 
resection. Lymphangiography revealed ab-
normal lymph nodes in both the pelvic and 
para-aortic areas. The initial bone scan re-
sults were negative. He was treated by the 
technique I have described and did fairly 
well following therapy. However, approx-
imately five months later, the patient de-
veloped osseous metastases. The kidneys 
and lumbarspine were normal butthe dorsal 
spine and ribs were involved with metas-
tases. This bone scan demonstrates that the 
hematogenous metastases start just above 
the level of our treatment portal. Similar 
cases are reported by others. Therefore, we 
are not yet sure where to classify the patient 
who already has para-aortic lymph node 
metastases. 
Summary 
Advances in our knowledge about the 
spread of carcinoma of the prostate, as well 
as improvements in equipment and the 
development of sophist icated radiat ion 
therapy treatment p lann ing techniques, 
have led us to attempt curative therapy in 
patients who are beyond the scope of surgi-
cal cure. The results reported to date are 
preliminary. Cooperative randomized trials 
are necessary in order to accumulate a large 
enough number of patients for valid statisti-
cal data. The dilemma of where to classify 
the patient with para-aortic lymph node 
metastasis is yet to be resolved. My impres-
sion is that once these nodes are grossly 
involved, hematogenous dissemination is 
very likely. Perhaps in the future, some 
combinationof chemotherapy and radiation 
therapy wi l l provide more satisfying results. 
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